Single-blind, Clinical Study of the Immunogenicity and Reactogenicity of SB Biologicals' dTpa, pa Vaccines and a Td Vaccine, Given as a Booster Dose to Healthy Adults, From the Age of 18 Years Onwards
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 550
- Primary Endpoint
- Occurrence of solicited local and general symptoms
Study Overview
Brief Summary
The aim of the study is to assess the safety and immunogenicity of GlaxoSmithKline Biologicals' (formerly known as SmithKline Beecham Biologicals) combined diphtheria-tetanus-acellular pertussis vaccine in healthy adults, from the age of 18 onwards, in Australia.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •At least 18 years of age at the time of the vaccination
- •Written informed consent has been obtained
Exclusion Criteria
- •Evidence of confirmed pertussis disease within the previous 5 years
- •History of diphtheria or tetanus vaccination within the past 5 years Females must not be pregnant or lactating They must either surgically sterilized or one year post-menopausal or if they are of childbearing potential, they must be abstinent or have used adequate contraceptive precautions (or one month prior to the booster vaccination, and must agree to continue such precautions for 2 months after completion of the vaccination.
- •History of diphtheria or tetanus disease
- •History of allergic disease likely to be stimulated by the vaccination
- •Major congenital defects or serious chronic illness
- •History of progressive neurological disease
- •Immunosuppressive therapy
- •Any suspected or confirmed immune disorder
- •Immunoglobulin therapy or administration of any blood products within the previous three months or during the study period
- •Acute febrile illness (>37.5°C, axillary or oral temperature) at the time of planned vaccination
- •Administration of an investigational or non registered drug or vaccine within 30 days prior to the start of the present trial
- •Simultaneous administration of a vaccine not foreseen by the study protocol, within 30 days prior to the start of the present trial
- •Any severe or serious adverse experience having occurred after previous administration of DTP vaccine i.e:
- •an immediate anaphylactic or unacceptable reaction to the investigator's opinion, to a previous dose of diphtheria tetanus pertussis whole-cell vaccine, i.e. :
- •encephalopathy
- •fever > 40.5°C (105°F), rectal temperature, occurring after vaccination with diphtheria tetanus pertussis whole-cell vaccine and not due to another identifiable cause.
- •collapse or shock-like state
- •persistent, inconsolable crying lasting > 3 hours
- •seizures with or without fever
- •systemic allergic or neurologic reactions following a previous dose of tetanus and diphtheria toxoids vaccine
- •Exclusion from long term follow-up of antibody persistence : Evidence of confirmed pertussis, diphtheria or tetanus disease or vaccination against these diseases since previous study visit
Arms & Interventions
Group A
Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
Intervention: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine (Biological)
Group B
Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
Intervention: GSK Biologicals' acellular pertussis vaccine (Biological)
Group B
Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
Intervention: Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine (Biological)
Group C
Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
Intervention: GSK Biologicals' acellular pertussis vaccine (Biological)
Group C
Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
Intervention: Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine (Biological)
Outcomes
Primary Outcomes
Occurrence of solicited local and general symptoms
Time Frame: Within the 15-day (Day 0 - Day 14) follow-up period after the first injection
Secondary Outcomes
- Immunogenicity with respect to components of the study vaccines(2, 3, 4 and 5 years after the vaccination)
- Occurrence of solicited local symptoms and fever(Within the 15-day (Day 0 - Day 14) follow-up period after the second injection)
- Occurrence of general solicited symptoms to vaccination, other than fever(Within the 15-day (Day 0 - Day 14) follow-up period after each vaccine administration)
- Occurrence of unsolicited symptoms(Within 31 days (Day 0 - Day 30) after each vaccine administration)
- Occurrence of serious adverse experiences to vaccination(Within 31 days (Day 0 - Day 30) after each vaccine administration)
- Immunogenicity with respect to components of the study vaccines(One year after the vaccination in a subset of subjects from all the groups)
- Immunogenicity with respect to components of the study vaccines(One month after the first injection)
- Immunogenicity with respect to components of the study vaccines(One month after the second injection)
- Immunogenicity with respect to components of the study vaccines(Immediately prior to the booster vaccination)